quinacrine has been researched along with Acute Liver Injury, Drug-Induced in 11 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Excerpt | Relevance | Reference |
---|---|---|
"Quinacrine (QUIN) is a well known inhibitor of PLA2." | 5.29 | Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis. ( Castro, JA; de Toranzo, EG; González Padrón, A, 1993) |
"Quinacrine (QUIN) is a well known inhibitor of PLA2." | 1.29 | Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis. ( Castro, JA; de Toranzo, EG; González Padrón, A, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (45.45) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 3 (27.27) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fourches, D | 1 |
Barnes, JC | 1 |
Day, NC | 1 |
Bradley, P | 1 |
Reed, JZ | 1 |
Tropsha, A | 1 |
Liu, Z | 1 |
Shi, Q | 1 |
Ding, D | 1 |
Kelly, R | 1 |
Fang, H | 1 |
Tong, W | 1 |
Warner, DJ | 1 |
Chen, H | 1 |
Cantin, LD | 1 |
Kenna, JG | 1 |
Stahl, S | 1 |
Walker, CL | 1 |
Noeske, T | 1 |
Karamanakos, PN | 1 |
Scoazec, JY | 1 |
Krolak-Salmon, P | 1 |
Casez, O | 1 |
Besson, G | 1 |
Thobois, S | 1 |
Kopp, N | 1 |
Perret-Liaudet, A | 1 |
Streichenberger, N | 1 |
CRADDOCK, WL | 1 |
Reuber, MD | 1 |
Lijinsky, W | 1 |
Araki, H | 1 |
Peck, RC | 1 |
Lefer, AM | 1 |
González Padrón, A | 1 |
de Toranzo, EG | 1 |
Castro, JA | 1 |
Ungemach, FR | 1 |
Gibb, W | 1 |
Isenberg, DA | 1 |
Snaith, ML | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092] | Phase 2 | 69 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -2.4 |
Quinacrine | -2.2 |
ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 13.0 |
Quinacrine | 12.6 |
An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | -23.2 |
Quinacrine | -13.2 |
Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 3.2 |
Quinacrine | 0.3 |
The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2
Intervention | units on a scale (Mean) |
---|---|
Placebo | -6.9 |
Quinacrine | -3.9 |
"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | units on a scale (Mean) |
---|---|
Placebo | 0.8 |
Quinacrine | 0.3 |
Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months
Intervention | number of words generated (Mean) |
---|---|
Placebo | -3.2 |
Quinacrine | -2.2 |
Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2
Intervention | participants (Number) |
---|---|
Placebo | 19 |
Quinacrine | 13 |
11 other studies available for quinacrine and Acute Liver Injury, Drug-Induced
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Could quinacrine prevent 'halothane hepatitis'?
Topics: Anesthetics, Inhalation; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1 Inhibitors; | 2009 |
Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease.
Topics: Antimalarials; Chemical and Drug Induced Liver Injury; Creutzfeldt-Jakob Syndrome; Humans; Quinacrin | 2003 |
Toxic hepatitis presumably produced by massive prolonged ingestion of atabrine: a case report with autopsy findings.
Topics: Autopsy; Chemical and Drug Induced Liver Injury; Hepatitis; Hepatitis A; Quinacrine; Viral Vaccines | 1950 |
Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.
Topics: Animals; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Female; Heart Atria; Heart Diseas | 1984 |
Biphasic actions of chlorpromazine and mepacrine on modulation of hepatic cell injury in the perfused cat liver.
Topics: Amines; Animals; Cathepsin D; Cathepsins; Cats; Chemical and Drug Induced Liver Injury; Chlorpromazi | 1981 |
Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis.
Topics: Animals; Body Temperature; Calcium; Carbon Radioisotopes; Carbon Tetrachloride; Chemical and Drug In | 1993 |
Prevention of liver cell damage following lipid peroxidation by depression of lysophosphatide formation.
Topics: Animals; Bromotrichloromethane; Chemical and Drug Induced Liver Injury; Chlorpromazine; Enzyme Activ | 1989 |
Mepacrine induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Quinacrine | 1985 |